We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-3.47%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$119B
AUM Growth
-$5.47B
Cap. Flow
+$963M
Cap. Flow %
0.81%
Top 10 Hldgs %
23.93%
Holding
4,385
New
262
Increased
2,061
Reduced
1,644
Closed
273

Sector Composition

Rank Sector Weight
1 Technology 14.55%
2 Financials 8.81%
3 Healthcare 8.45%
4 Industrials 6.22%
5 Consumer Discretionary 6.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EWS icon
3576
iShares MSCI Singapore ETF
EWS
$1.16B
$231K ﹤0.01%
11,079
-97
-0.9% -$2.03K
AMTX icon
3577
Aemetis
AMTX
$126M
$230K ﹤0.01%
18,120
+7,097
+64% +$78.2K
SOCL icon
3578
Global X Social Media ETF
SOCL
$91.4M
$230K ﹤0.01%
5,440
+53
+1% +$2.44K
XPEV icon
3579
XPeng
XPEV
$11.3B
$230K ﹤0.01%
8,354
+372
+5% +$13.2K
NBO
3580
DELISTED
Neuberger Berman New York Municipal Fund Inc.
NBO
$230K ﹤0.01%
19,832
+6,300
+47% +$75.4K
ACP
3581
abrdn Income Credit Strategies Fund
ACP
$644M
$229K ﹤0.01%
23,379
+137
+0.6% +$1.37K
BTAI icon
3582
BioXcel Therapeutics
BTAI
$34.9M
$229K ﹤0.01%
+684
New +$198K
PBI icon
3583
Pitney Bowes
PBI
$2.28B
$229K ﹤0.01%
44,041
+16,464
+60% +$89.2K
WMK icon
3584
Weis Markets
WMK
$1.77B
$229K ﹤0.01%
3,207
-897
-22% -$59.5K
DEN
3585
DELISTED
Denbury Inc.
DEN
$229K ﹤0.01%
2,911
-11,501
-80% -$850K
BWIN
3586
Baldwin Insurance Group
BWIN
$2.99B
$228K ﹤0.01%
8,504
-1,400
-14% -$40.3K
MRTX
3587
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$228K ﹤0.01%
2,776
+73
+3% +$7.46K
BKN
3588
DELISTED
BlackRock Investment Quality Municipal Trust
BKN
$226K ﹤0.01%
15,697
+500
+3% +$7.98K
PDN icon
3589
Invesco FTSE RAFI Developed Markets ex-US Small-Mid ETF
PDN
$367M
$226K ﹤0.01%
6,565
-1,424
-18% -$49.9K
SAFE
3590
Safehold
SAFE
$1.1B
$226K ﹤0.01%
1,986
-335
-14% -$39.2K
ALCO icon
3591
Alico
ALCO
$304M
$225K ﹤0.01%
6,001
+372
+7% +$12.9K
CDE icon
3592
Coeur Mining
CDE
$19B
$225K ﹤0.01%
50,555
+3,050
+6% +$14.5K
TCOM icon
3593
Trip.com Group
TCOM
$28.3B
$225K ﹤0.01%
9,728
+326
+3% +$8.21K
MAGN
3594
Magnera Corp
MAGN
$433M
$225K ﹤0.01%
1,395
-960
-41% -$190K
LKFN icon
3595
Lakeland Financial Corp
LKFN
$1.56B
$224K ﹤0.01%
3,075
+179
+6% +$14.3K
PBF icon
3596
PBF Energy
PBF
$8.81B
$224K ﹤0.01%
+9,203
New +$174K
WEA
3597
Western Asset Premier Bond Fund
WEA
$125M
$224K ﹤0.01%
18,672
DVYE icon
3598
iShares Emerging Markets Dividend ETF
DVYE
$1.21B
$223K ﹤0.01%
6,809
+1,522
+29% +$55.4K
GOOD
3599
Gladstone Commercial Corp
GOOD
$641M
$223K ﹤0.01%
10,141
-6,439
-39% -$145K
HL icon
3600
Hecla Mining
HL
$11.9B
$223K ﹤0.01%
33,867
+8,886
+36% +$51.4K

Similar funds

Raymond James & Associates's Q1 2022 Portfolio in Review

As of Q1 2022, Raymond James & Associates held 4,385 positions worth $119B, down 4.4% from $124B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q1 2022 filing shows 262 new, 2,061 increased, 1,644 reduced and 273 closed positions. Its largest new stake was Shell: 688,334 shares worth $37.8M. The largest sale was iShares Ultra Short Duration Bond Active ETF, an estimated $172M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q1 2022 buy was Shell: 688,334 shares worth $37.8M.
  • Raymond James & Associates added most to Broadcom in Q1 2022, an estimated $236M increase.
  • Raymond James & Associates's biggest Q1 2022 reduction was iShares Ultra Short Duration Bond Active ETF, cutting an estimated $172M.
  • Raymond James & Associates fully exited IHS Markit Ltd. Common Shares in Q1 2022, selling an estimated $154M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $119B portfolio in Q1 2022.
  • Raymond James & Associates opened 262 new positions and closed 273 in Q1 2022.
  • Raymond James & Associates's portfolio value fell 4.4% quarter-over-quarter to $119B.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.